Recall of HIV Types 1 &2 (Synthetic Peptide)

LOT NUMBER / EXPIRATION DATE: 105VP1     1/25/2003 Redmond, WA The recalling firm identified a small number of microwell plates in this lot that are performing outside of expected performance ranges as indicated by invalid (low) HIV-1 and HIV-2 Positive Controls and elevated Negative Control values. Consignees have been asked to contact the manufacturer to arrange for product return.

/index.php?option=com_iwpfile&file=/dir_01/he2002_2567.pdf

/index.php?option=com_iwpfile&file=/dir_01/he2002_2566.pdf

/index.php?option=com_iwpfile&file=/dir_01/he2002_2565.pdf

/index.php?option=com_iwpfile&file=/dir_01/he2002_2564.pdf

Call for Development of Blood Donor Screening and Supplemental Tests for Infections with West Nile Virus (WNV)

10/3/2002


T02-37 Media Inquiries: 301-436-2335
October 2, 2002 Consumer Inquiries: 888-INFO-FDA

CONSUMERS ADVISED OF RISKS ASSOCIATED WITH EATING RAW AND LIGHTLY COOKED SPROUTS

O157:H7 outbreak associated with alfalfa sprouts. This advisory is also being updated to specifically include raw and lightly cooked mung bean sprouts.


ry

OSHA, CONSTRUCTION MANAGEMENT ASSOCIATION OF AMERICA FORM ALLIANCE

Goal is Better Health and Safety for the Construction Industry

WASHINGTON -- The Occupational Safety and Health Administration and the Construction Management Association of America (CMAA) have established an Alliance to share their collective expertise to help prevent injuries and illnesses in construction workplaces, announced OSHA Administrator John L. Henshaw today.


ts Date: Oct. 3, 2002 Contacts: Christine Stencel, Media Relations Officer Chris Dobbins, Media Relations Assistant (202) 334-2138; e-mail <news@nas.edu> FOR IMMEDIATE RELEASE Broader Federal Protections, Other Reforms Needed To Ensure Safety of Human Research Participants WASHINGTON -- Broader federal oversight is needed to ensure that the health and well-being of people who are enrolled in research studies, whether publicly or privately funded, are better-protected, says a new report from the Institute of Medicine (IOM) of the National Academies.

/index.php?option=com_iwpfile&file=/dir_01/he2002_2556.pdf

Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.